Related Experiment Video
Updated: Jul 16, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Emerging drugs in neuropathic pain
Ian Gilron1, Terence J Coderre
1Clinical Pain Research, Queen's University, Kingston, Ontario, ON, Canada. gilroni@post.queensu.ca
Expert Opinion on Emerging Drugs
|March 16, 2007
Summary
Neuropathic pain affects millions, with current treatments often ineffective and causing side effects. New drug development shows promise, but comparative studies are needed to confirm the value of novel neuropathic pain therapies.
Area of Science:
- Neurology
- Pharmacology
- Pain Management
Background:
- Neuropathic pain is a prevalent and debilitating condition impacting 3-8% of the global population.
- Current therapeutic options for neuropathic pain are limited in efficacy and associated with frequent adverse effects.
- Despite extensive preclinical research identifying numerous targets, predicting clinical success for new neuropathic pain drugs remains challenging.
Purpose of the Study:
- To review the landscape of pharmaceutical development for neuropathic pain.
- To highlight emerging therapeutic strategies and drug candidates.
- To advocate for comparative studies to validate the clinical value of novel agents.
Main Methods:
- Comprehensive review of recent pharmaceutical development in neuropathic pain.
- Analysis of drugs in clinical development, including various molecular targets and therapeutic classes.
- Identification of promising therapeutic strategies such as topical agents, combination therapies, and gene-related therapies.
Main Results:
- Over 50 new molecular entities targeting diverse pathways are in clinical development for neuropathic pain.
- Eight drugs are currently in Phase III clinical trials.
- Significant advancements in understanding neuropathic pain neurobiology have fueled pharmaceutical innovation.
Conclusions:
- The field of neuropathic pain therapeutics is rapidly evolving with numerous novel agents under investigation.
- Topical therapies, analgesic combinations, and future gene-related therapies represent promising avenues.
- Implementing comparative studies is crucial to demonstrate the added value of new neuropathic pain treatments and improve patient care.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:24Local Anesthetics: Differential Sensitivity of Nerve Fibers
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...